MedTrace Logo

A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

NCT01349036 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-03-03

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.

Conditions

Interventions

DRUG

PLX3397

Capsules administered once or twice daily, continuous dosing

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-03
Primary Completion
2013-11-05
Completion
2013-11-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01349036 on ClinicalTrials.gov